Skip to content
DataLookout
Menu

NCT07468916

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Sep 29, 2026 to Jan 30, 2027 Show 6 more changesShow less
    • Eligibility criteria expanded, about 13 words
    • Primary completion pushed from Sep 30, 2031 to Jan 30, 2032
    • Study completion pushed from Sep 30, 2032 to Jan 30, 2033
    • Secondary endpoints: details revised at 11 of 14 entries
    • Study description revised
    • Site details revised
  2. Notable Primary completion pushed from Mar 30, 2031 to Sep 30, 2031
    • Start date: Mar 29, 2026 to Sep 29, 2026
    • Study completion pushed from Mar 30, 2032 to Sep 30, 2032
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Overall response
Timeframe: Up to 24 months
Incidence of adverse events
Timeframe: Up to 24 months

Secondary (14)

Cytogenetics
Mutation profile
Chronic myelomonocytic leukemia-specific prognostic scoring system - molecular risk
Clinical benefit
Progression-free survival
Show 9 moreShow less
Overall survival
Change in mutant allele frequencies
Percent change in splenomegaly
Changes in myeloproliferative neoplasm symptom burden
Time to response
Duration of response
Changes in packed red blood cell transfusion burden
Changes in bone marrow morphology and fibrosis
Change in cytokine profile

Arms and interventions

Treatment (ropeginterferon alfa-2b)Experimental

Patients receive ropeginterferon alfa-2b SC on days 1 and 15 of each cycle. Cycles repeat every 28 days for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy, CT, and collection of blood samples throughout the trial.

Procedures: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography

Other: Questionnaire Administration

Biologicals: Ropeginterferon Alfa-2B

Sites

1 site in 1 country

  • UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, California, United States